

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Louis Panaccio
Date of last notice	6 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	4 June 2025 (United States) / 5 June 2025 (Australia) – RSUs and Options 5 June 2025 (United States) / 6 June 2025 (Australia) – Common Stock

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>a) 9,200 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CHES Depositary Interests ("CDIs")) ("RSUs")</p> <p>b) 70,460 CDIs CHES Depositary Interests in the Company quoted on the ASX ("CDIs") (representing beneficial ownership in 14,092 shares of common stock), of which Mr Panaccio is the registered holder.</p> <p>c) 2,550 unquoted options in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("Options") expiring 23 Dec 2031 ex USD \$12.18; and</p> <p>d) 5,395 options expiring 13 Dec 2032 ex USD \$6.95,</p> <p>e) 23,114 of common stock of the Company (which may be represented by CDIs)</p> <p>f) 2,646 options expiring 7 June 2033 ex USD \$14.17</p> <p>g) 3,943 Options expiring 6 June 2034, ex USD \$9.51</p> <p>of which Mr Panaccio is the registered holder.</p> <p>29,860 CDIs (representing beneficial ownership in 5,972 shares of common stock), of which Tercus Pty Ltd atf The Panaccio Superannuation Fund is the registered holder. Mr Panaccio is one of two directors (along with his spouse), and one of two 50% shareholders (along with his spouse), of Tercus Pty Ltd (atf The Panaccio Superannuation Fund), as well as a beneficiary of The Panaccio Superannuation Fund. Mr Panaccio's relevant interest arises by virtue of sections 608(1)(b) and (c) of the Corporations Act 2001 (Cth).</p>
<p>Class</p>	<p>a) RSUs</p> <p>b) Options</p> <p>c) Common Stock</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Number acquired	<p>a) 10,022 RSUs</p> <p>b) 4,295 Options expiring 22 January 2035, ex USD \$8.73</p> <p>c) 9,200 Common Stock</p>
Number disposed	9,200 RSUs
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration
No. of securities held after change	<p>a) 10,022 RSUs</p> <p>b) 70,460 CDIs</p> <p>c) 2,550 options expiring 23 Dec 2031 ex USD \$12.18; and</p> <p>d) 5,395 options expiring 13 Dec 2032 ex USD \$6.95,</p> <p>e) 32,314 of common stock of the Company (which may be represented by CDIs)</p> <p>f) 2,646 options expiring 7 June 2033 ex USD \$14.17</p> <p>g) 3,943 Options expiring 6 June 2034, ex USD \$9.51</p> <p>h) 4,295 Options expiring 22 January 2035, ex USD \$8.73</p> <p>of which Mr Panaccio is the registered holder.</p> <p>29,860 CDIs of which Tercus Pty Ltd ATF The Panaccio Superannuation Fund is the registered holder (as noted above).</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	<p>Issue of Options and RSUs as approved by Shareholders at the 2025 ASM.</p> <p>Issue of Common Stock upon conversion of Restricted Stock Units (RSUs).</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jan Stern Reed
Date of last notice	6 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	4 June 2025 (United States) / 5 June 2025 (Australia) – RSUs and Options 5 June 2025 (United States) / 6 June 2025 (Australia) – Common Stock

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>12,091 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CHES Depository Interests ("CDIs") ("RSUs").</p> <p>28,898 of common stock of the Company (which may be represented by CDIs).</p> <p>7,475 unquoted options in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("Options") expiring 23 Dec 2031 ex USD \$12.18</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95</p> <p>2,646 Options expiring 7 June 2033 ex USD \$14.17</p> <p>3,943 Options expiring 6 June 2034, ex USD \$9.51</p>
<p>Class</p>	<p>a) RSUs b) Option c) Common Stock</p>
<p>Number acquired</p>	<p>a) 10,022 RSUs b) 4,295 Options expiring 22 January 2035, ex USD \$8.73 c) 9,200 Common Stock (6 June 2025 (Australia))</p>
<p>Number disposed</p>	<p>9,200 RSUs (6 June 2025 (Australia))</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Nil consideration</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>12,913 RSUs</p> <p>38,098 of common stock of the Company (which may be represented by CDIs).</p> <p>7,475 Options expiring 23 Dec 2031 ex USD \$12.18</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95</p> <p>2,646 Options expiring 7 June 2033 ex USD \$14.17</p> <p>3,943 Options expiring 6 June 2034, ex USD \$9.51</p> <p>4,295 Options expiring 22 January 2035, ex USD \$8.73</p>
<p>Nature of change</p> <p>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of Options and RSUs as approved by Shareholders at the 2025 ASM.</p> <p>Issue of Common Stock upon conversion of Restricted Stock Units (RSUs).</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
<p>No. and class of securities to which interest related prior to change</p> <p>Note: Details are only required for a contract in relation to which the interest has changed</p>	N/A
Interest acquired	N/A
Interest disposed	N/A
<p>Value/Consideration</p> <p>Note: If consideration is non-cash, provide details and an estimated valuation</p>	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Interest after change	N/A
-----------------------	-----

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jeremy Curnock Cook
Date of last notice	6 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	4 June 2025 (United States) / 5 June 2025 (Australia) – RSUs and Options 5 June 2025 (United States) / 6 June 2025 (Australia) – Common Stock

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<p>9,200 unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CHESSE Depository Interests ("CDIs") ("RSUs")</p> <p>20,614 common stock of the Company (which may be represented by CDIs) ("Common Stock")</p> <p>2,550 Options expiring 23 Dec 2031 ex USD \$12.18</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95</p> <p>2,646 Options expiring 7 June 2033 ex USD \$14.17</p> <p>3,943 Options expiring 6 June 2034, ex USD \$9.51</p>
<p>Class</p>	<p>a) RSUs</p> <p>b) Options</p> <p>c) Common Stock</p>
<p>Number acquired</p>	<p>a) 10,022 RSUs</p> <p>b) 4,295 Options expiring 22 January 2035, ex USD \$8.73</p> <p>c) 9,200 Common Stock</p>
<p>Number disposed</p>	<p>9,200 RSUs</p>
<p>Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small></p>	<p>Nil consideration</p>
<p>No. of securities held after change</p>	<p>10,022 RSUs</p> <p>29,814 Common Stock</p> <p>2,550 Options expiring 23 Dec 2031 ex USD \$12.18</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95</p> <p>2,646 Options expiring 7 June 2033 ex USD \$14.17</p> <p>3,943 Options expiring 6 June 2034, ex USD \$9.51</p> <p>4,295 Options expiring 22 January 2035, ex USD \$8.73</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of Options and RSUs as approved by Shareholders at the 2025 ASM.</p> <p>Issue of Common Stock upon conversion of Restricted Stock Units (RSUs).</p>
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Suzanne Crowe
Date of last notice	9 December 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	4 June 2025 (United States) / 5 June 2025 (Australia) – RSUs and Options 5 June 2025 (United States) / 6 June 2025 (Australia) – Common Stock

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>9,200 RSUs</p> <p>22,990 CDIs</p> <p>23,114 of common stock of the Company (which may be represented by CDIs).</p> <p>2,550 Options expiring 23 Dec 2031 ex USD \$12.18.</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95.</p> <p>2,646 Options expiring 7 June 2033 ex USD \$14.17.</p> <p>3,943 Options expiring 6 June 2034, ex USD \$9.51</p>
Class	<p>a) RSUs</p> <p>b) Options</p> <p>c) Common Stock</p>
Number acquired	<p>a) 10,022 RSUs</p> <p>b) 4,295 Options expiring 22 January 2035, ex USD \$8.73</p> <p>c) 9,200 Common Stock</p>
Number disposed	9,200 RSUs
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil Consideration
No. of securities held after change	<p>10,022 RSUs</p> <p>22,990 CDIs</p> <p>32,314 of common stock of the Company (which may be represented by CDIs).</p> <p>2,550 Options expiring 23 Dec 2031 ex USD \$12.18.</p> <p>5,395 Options expiring 13 Dec 2032 ex USD \$6.95.</p> <p>2,646 Options expiring 7 June 2033 ex USD \$14.17.</p> <p>3,943 Options expiring 6 June 2034, ex USD \$9.51</p> <p>4,295 Options expiring 22 January 2035, ex USD \$8.73</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of Options and RSUs as approved by Shareholders at the 2025 ASM.</p> <p>Issue of Common Stock upon conversion of Restricted Stock Units (RSUs).</p>
---	--

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Cary Vance
Date of last notice	6 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	<ul style="list-style-type: none"> a) 4 June 2025 (United States) / 5 June 2025 (Australia) – RSUs and Options b) 5 June 2025 (United States) / 6 June 2025 (Australia) – Common Stock c) 6 June 2025 (United States) / 7 June 2025 (Australia) – Common Stock
No. of securities held prior to change	<p>16,116 Unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("RSUs")</p> <p>9,633 Common Stock</p> <p>7,092 Options expiring 7 June 2033, ex USD \$14.17.</p> <p>3,943 Options expiring 6 June 2034, ex USD \$9.51</p>

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Class	a) RSUs b) Options c) Common Stock
Number acquired	a) 10,022 RSUs b) 4,295 Options expiring 22 January 2035, ex USD \$8.73 c) 9,200 Common Stock (6 June 2025 (Australia)) d) 3,458 Common Stock (7 June 2025 (Australia))
Number disposed	a) 9,200 RSUs (6 June 2025 (Australia)) b) 3,458 RSUs (7 June 2025 (Australia))
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration
No. of securities held after change	13,480 RSUs 22,291 Common Stock 7,092 Options expiring 7 June 2033 ex USD \$14.17. 3,943 Options expiring 6 June 2034, ex USD \$9.51 4,295 Options expiring 22 January 2035, ex USD \$8.73
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Options and RSUs as approved by Shareholders at the 2025 ASM. Issue of Common Stock upon conversion of Restricted Stock Units (RSUs).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Robert McNamara
Date of last notice	11 March 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	N/A
Date of change	<ul style="list-style-type: none"> a) 4 June 2025 (United States) / 5 June 2025 (Australia) – RSUs and Options b) 5 June 2025 (United States) / 6 June 2025 (Australia) – Common Stock c) 6 June 2025 (United States) / 7 June 2025 (Australia) – Common Stock
No. of securities held prior to change	16,116 RSUs (Restricted Stock Units) 30,633 Common Stock 7,092 Options expiring 7 June 2033 ex USD \$14.17 3,943 Options expiring 6 June 2034, ex USD \$9.51

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Class	a) RSUs b) Options c) Common Stock
Number acquired	a) 10,022 RSUs b) 4,295 Options expiring 22 January 2035, ex USD \$8.73 c) 9,200 Common Stock (6 June 2025 (Australia)) d) 3,458 Common Stock (7 June 2025 (Australia))
Number disposed	a) 9,200 RSUs (6 June 2025 (Australia)) b) 3,458 RSUs (7 June 2025 (Australia))
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Nil consideration
No. of securities held after change	13,480 RSUs (Restricted Stock Units) 43,291 Common Stock 7,092 Options expiring 7 June 2033 ex USD \$14.17 3,943 Options expiring 6 June 2034, ex USD \$9.51 4,295 Options expiring 22 January 2035, ex USD \$8.73
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Options and RSUs as approved by Shareholders at the 2025 ASM. Issue of Common Stock upon conversion of Restricted Stock Units (RSUs).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity: AVITA Medical, Inc. ("Company")
ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	James Corbett
Date of last notice	6 June 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	N/A
Date of change	4 June 2025 (United States) / 5 June 2025 (Australia)

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<p>2,891 RSUs (unquoted restricted stock units in the Company to acquire shares of common stock of the Company (which may be represented by CHESSE Depository Interests ("CDIs")) ("RSUs")</p> <p>8,689 of common stock of the Company (which may be represented by CDIs)</p> <p>7,475 unquoted options in the Company to acquire shares of common stock of the Company (which may be represented by CDIs) ("Options") expiring 23 Dec 2031 ex USD \$12.18</p> <p>226,296 Options expiring 29 Sep 2032 ex USD \$5.64</p> <p>100,000 Options expiring 7 June 2033 ex USD \$14.17</p> <p>350,000 Options expiring 4 January 2034, ex USD \$12.64</p>
Class	Options
Number acquired	520,000 Options expiring 22 January 2035, ex USD \$8.73
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil consideration

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

No. of securities held after change	<p>2,891 RSUs</p> <p>8,689 of common stock of the Company (which may be represented by CDIs)</p> <p>7,475 Options expiring 23 Dec 2031 ex USD \$12.18</p> <p>226,296 Options expiring 29 Sep 2032 ex USD \$5.64</p> <p>100,000 Options expiring 7 June 2033 ex USD \$14.17</p> <p>350,000 Options expiring 4 January 2034, ex USD \$12.64</p> <p>520,000 Options expiring 22 January 2035, ex USD \$8.73</p>
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Options as approved by Shareholders at the 2025 ASM.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

Interest after change	N/A
-----------------------	-----

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

+ See chapter 19 for defined terms.

For personal use only